Resistance to the HIV Protease Inhibitor Amprenavir In Vitro and in Clinical StudiesA Review

被引：0
|
作者：
Margaret Tisdale
Richard Myers
Sharon Randall
Michael Maguire
Mounir Ait-Khaled
Rob Elston
Wendy Snowden
机构：
[1] GlaxoWellcome Research and Development,Clinical Virology and Surrogates Unit
来源：
Clinical Drug Investigation | 2000年 / 20卷
关键词：
Lamivudine; Zidovudine; Ritonavir; Indinavir; Saquinavir;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Amprenavir (APV) is a highly active and selective HIV protease inhibitor (PI) that is used for the treatment of HIV infection in adults and children. In this review we present data from extensive resistance studies undertaken during the development of amprenavir. These include in vitro and clinical studies where the phenotype and genotype of HIV protease was determined after treatment with amprenavir either as the single PI [alone or with nucleoside reverse transcriptase inhibitors (NRTIs)] or in combination with other PIs. In addition, cross-resistance with other PIs has been examined to help position use of amprenavir in the clinic.
引用
收藏
页码：267 / 285
页数：18
相关论文
共 50 条
  • [41] HIV protease inhibitor
    Tranter, D
    DRUG DISCOVERY TODAY, 2001, 6 (04) : 213 - 214
  • [42] Structural and Thermodynamic Basis of Amprenavir/Darunavir and Atazanavir Resistance in HIV-1 Protease with Mutations at Residue 50
    Mittal, Seema
    Bandaranayake, Rajinthna M.
    King, Nancy M.
    Prabu-Jeyabalan, Moses
    Nalam, Madhavi N. L.
    Nalivaika, Ellen A.
    Yilmaz, Nese Kurt
    Schiffer, Celia A.
    JOURNAL OF VIROLOGY, 2013, 87 (08) : 4176 - 4184
  • [43] Novel HIV drug resistance mechanism leading to protease inhibitor (PI) resistance in response to a high genetic barrier PI in vitro
    Nijhuis, M
    van Maarseveen, NM
    Schipper, P
    Goedegebuure, IW
    Heilek-Snyder, G
    Cammack, N
    Boucher, CAB
    ANTIVIRAL THERAPY, 2004, 9 (04) : U43 - U43
  • [44] Amprenavir: An option for HIV patients failing treatment with other protease inhibitors?
    不详
    Drugs & Therapy Perspectives, 2001, 17 (13) : 1 - 5
  • [45] Switch to amprenavir/ritonavir demonstrated superior efficacy compared to the continuation of a protease inhibitor in multiple protease inhibitor-experienced HIV-1-infected subjects with virological failure
    Cattelan, AM
    Pulido, F
    Stark, T
    Elston, R
    ANTIVIRAL THERAPY, 2002, 7 (03) : L71 - L72
  • [46] IN VITRO EFFICACY OF A NON-CONVENTIONAL (FOLDING) HIV-1 PROTEASE INHIBITOR WITHOUT SELECTION OF RESISTANCE
    Ferramosca, S.
    Lo Cicero, M.
    Laface, A. E.
    Sirianni, F.
    Cesana, E.
    Provasi, D.
    Tiana, G.
    Galli, M.
    Moroni, M.
    Clivio, A.
    Broglia, R. A.
    Rusconi, S.
    INFECTION, 2009, 37 : 23 - 23
  • [47] Resistance to HIV protease inhibitors: Mechanisms and clinical consequences
    de Mendoza, C
    Soriano, V
    CURRENT DRUG METABOLISM, 2004, 5 (04) : 321 - 328
  • [48] Virological and clinical implications of resistance to HIV protease inhibitors
    Condra, JH
    AIDS, 1998, 12 : S4 - S4
  • [49] In vitro selection strategy and characterization of resistance to a novel highly potent HIV protease inhibitor SPI-256
    Afonina, E.
    Gulnik, S.
    Yokoe, H.
    Erickson, J.
    ANTIVIRAL THERAPY, 2006, 11 (05) : S30 - S30
  • [50] The HIV protease inhibitor, ritonavir, dysregulates human platelet function in vitro
    Loelius, Shannon G.
    Lannan, Katie L.
    Blumberg, Neil
    Phipps, Richard P.
    Spinelli, Sherry L.
    THROMBOSIS RESEARCH, 2018, 169 : 96 - 104
12345